Cellyan Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Cash & Equivalents	0.19	0.75	0.62	0.52
Short-Term Investments	2.29	2.26	-	-
Cash & Short-Term Investments	2.48	3.01	0.62	0.52
Cash Growth	579.84%	385.10%	18.10%	-
Accounts Receivable	5.09	4.66	3.7	1.65
Other Receivables	0.69	0.51	1.28	0.39
Total Trade Receivables	5.78	5.16	4.98	2.03
Inventory	0.59	0.56	0.93	0.19
Other Current Assets	0	0	1.27	-
Total Current Assets	8.86	8.73	7.8	2.75
Net Property, Plant & Equipment	0.69	0.59	0.83	0.65
Other Intangible Assets	0.09	0.1	0.03	0
Total Assets	9.63	9.42	8.67	3.41
Accounts Payable	1.57	1.82	1.92	1.84
Accrued Expenses	0.12	0.11	0.22	0.02
Short-Term Debt	-	-	0.03	-
Current Portion of Long-Term Debt	0.36	0.37	0.18	0.06
Current Portion of Leases	0.45	0.49	0.63	0.36
Unearned Revenue	0.53	0.12	0.19	0.27
Total Current Liabilities	3.03	2.92	3.18	2.55
Long-Term Debt	1.33	1.5	1.12	0.12
Long-Term Leases	0.13	0.01	0.12	0.15
Total Long-Term Liabilities	1.46	1.51	1.24	0.27
Total Liabilities	4.49	4.43	4.41	2.82
Common Stock	0.01	0.01	0.01	0.01
Additional Paid-in Capital	3.46	3.46	2.72	0.38
Accumulated Other Comprehensive Income	0.01	0.01	-0	-0
Retained Earnings	1.66	1.5	1.53	0.2
Shareholders' Equity	5.14	4.99	4.25	0.59
Total Liabilities & Equity	9.63	9.42	8.67	3.41
Total Debt	2.27	2.37	2.09	0.69
Net Cash (Debt)	0.21	0.63	-1.47	-0.17
Net Cash Growth	-66.92%	-	-	-
Net Cash Per Share	0.02	0.06	-0.20	-0.02
Book Value	5.14	4.99	4.25	0.59
Book Value Per Share	0.48	0.49	0.58	0.09
Tangible Book Value	5.05	4.89	4.22	0.58
Tangible Book Value Per Share	0.47	0.48	0.57	0.08

SEC Filings: 10-K · 10-Q